My research focus is to develop novel therapeutic strategies and to improve the clinical outcomes for children with incurable brain tumors. As a pediatric hematology/oncology fellow, my work directly led to the discovery of an activated novel KIAA1549-BRAF fusion oncogene in the majority of pediatric low-grade gliomas (PLGGs). This genomic abnormality has since been found to be a hallmark of PLGGs. After fellowship, I continued my research in the laboratory of Dr. Adam Resnick. Our initial findings in PNAS in March 2013 and laid the foundation for understanding BRAF fusion signaling and has opened the door to several multi-institutional collaborations.
- Education and Training
MD - Tulane University School of Medicine, New Orleans, LA
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology-Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA
MPH - Tulane University School of Public Health & Tropical Medicine, New Orleans, LA
- Titles and Academic Titles
Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
- Conditions Treated
- Departments and Services
- Research Interests
Pediatric low grade gliomas
Opsoclonus myoclonus ataxia syndrome
Minturn JE, Sievert AJ. Pediatric brain tumors. In: Florin T, Ludwig S. Netter's pediatrics. Philadelphia: Saunders; 2011.
Mueller S, Dik R, Yang X, Olow A, Gustafson C, DuBois S, Weiss W, Waanders AJ, Resnick, AC, and Haas-Kogan D. Effects of TORC1/2 inhibitor MLN0128 alone and in combination with MEK inhibition in BRAF mutated glioma cells. Neuro-Oncology. 17:iii1-iii40, 2015. Doi:10.1093/neuonc/nov061.75.
Waanders AJ, Silva A, Chen SS, Han H, Zhu Y, Boucher K, Jain P, Fierst T, Choudhari N, Mueller S, Haas-Kogan D, Storm PB, Resnick AC. Combinatorial pathway targeting approaches for BRAF-fusions associated with pediatric low-grade gliomas. Neuro-Oncology. 17:iii1-iii40, 2015. Doi:10.1093/neuonc/nov061.151.
Olow AK, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Berger MS, Gupta N, James CD, Haas-Kogan DA. Targeted combinatorial approach for treatment of pediatric low-grade gliomas in the context of BRAF V600E and KIAA1549:BRAF mutations. Neuro-Oncology. 17:iii1-iii40, 2015. Doi:10.1093/neuonc/nov061.153.
Sievert AJ, Lang SS, Silva A, Brewington D, Mueller S, Haas-Kogan DA, Storm PB, Resnick AC. Rationale for combinatorial therapeutics to inhibit BRAF fusion activation. Mol Cancer Ther. Nov 2013. 12:B272, doi:10.1158/1535-7163.
Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, Goldbery JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DTW, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, and Allen JC. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol. 2014 May 6. [Epub ahead of print]. PMID: 24803676
Goldberg EM, Titulaer M, de Blank PM, Sievert A, Ryan N. Anti-N-methyl-D aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of literature. Pediatr Neurol 2014 Feb; 50(2): 181-4. Doi: 10.1016/j.pediatrneurol.2013.10.002. Epub 2013 Oct 14.
Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, and Resnick AC. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. PNAS 2013 April; 110 (15): 5957-5962. Epub 2013 Mar 26. PMID: 23533272
Posters and Presentations
Lectures by Invitation
Waanders, AJ. “Opsoclonus Myoclonus Ataxia Syndrome,” Chair Clinical Conference, The Children’s Hospital of Philadelphia, Philadelphia, PA, May 2014.
“Targeting activating BRAF mutations in pediatric gliomas,” Neurosurgery Grand Rounds, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, August 2014.
Waanders, AJ. “Congenital brain tumors,” Abington Memorial Hospital Neonatology Grand Rounds, Abington Township, PA, November 2013.
Waanders, AJ. “Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas,” 2013 Pediatric Neuro-Oncology Basic and Translational Research Conference, Fort Lauderdale, FL, May 2013.
- Awards and Honors
2014- present, Sanford Endowed Chair for Pediatric Oncology Research
2009, Prize- CHOP Research Poster Day
1999-2003, Adopt-A-Student Scholarship, Tulane University SOM
1996, Philosophy Department Senior Student Award
1992-1996, Alpha Lambda Delta Honorary Society
1992-1996, Medallion and HEIS Scholarships for Academic Excellence
- Editorial and Academic Positions
2013-present, Molecular Cancer Therapeutics, reviewer
2012-present, Journal of Neuro-Oncology, reviewer
2011-present, Pediatric Blood and Cancer, reviewer
Academic and Institutional Committees
2014-present, St. Baldrick’s Foundation, Grant Review Committee
2011-present, Pediatric Protocol Review Committee, Division of Oncology, Children’s Hospital of Philadelphia
Memberships in Professional Organizations
2013- present, Co-Investigator, Pacific Pediatric Neuro-Oncology Consortium
2009- 2012, Pediatric Brain Tumor Consortium
2008- present, American Association for Cancer Research
2007- present, Society of Neuro-Oncology
2007- present, Children’s Oncology Group
2006- present, American Society of Pediatric Hematology/Oncology
2006-present, American Society of Clinical Oncology
- Awards and Honors